NCT02032173View on ClinicalTrials.gov

Efficacy and Safety of Lucentis® Use in Patients With Diabetic Macular Edema Evaluating a Spaced Out Follow-up After Intensive Treatment Phase

PHASE3TerminatedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

May 19, 2014

Primary Completion Date

April 29, 2015

Study Completion Date

April 29, 2015

Conditions
Macular EdemaMacular DegenerationDiabetes
Interventions
DRUG

Ranibizumab 0.5mg

Intravitreal injection with standard dose of 0.5 mg/0.05mL Pro re nata (PRN)

Trial Locations (10)

33000

Novartis Investigative Site, Bordeaux

69002

Novartis Investigative Site, Lyon

75015

Novartis Investigative Site, Paris

75940

Novartis Investigative Site, Paris

86021

Novartis Investigative Site, Poitiers

93009

Novartis Investigative Site, Bobigny

94000

Novartis Investigative Site, Créteil

94275

Novartis Investigative Site, Le Kremlin-Bicêtre

F-33076

Novartis Investigative Site, Bordeaux

06000

Novartis Investigative Site, Nice

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY